An EU-funded project that aims to improve the quality of life of children affected by chronic pain - who in most cases are treated with drugs that lack commercial authorisation - has just been launched. GAPP (GAbapentin in Paediatric Pain), which involves nine different countries from within and outside the EU, is the first international project to fully tackle this issue.
Further information: cordis.europa.eu